USPatentGranted
B1

Benzofurane derivatives

Granted 11 Mar 2003 · 2 office actions

Current assignee: MERCK PATENT GMBH · originally Merck & Co., Inc.

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Henning Bttcher, Bernd Helfert, Andreas Bathe · Examiner: Amelia Owens · AU 1625 · TC 1600

Application
10/030,471
filed 29 Jun 2000
Publication
Not published
not published
Patent· this page
US 6,531,503
granted 11 Mar 2003

Life of the patent

7 dated events
⤢ drag to zoom20002002200420062008201020122014201620182020ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Benzofurane derivatives of formula (I), wherein R and R have the meanings given in claim no. (1), and salts thereof are suitable for use as intermediate products in the synthesis of medicaments.

Description

11 parts
›The invention relates to benzofuran derivatives of the…

The invention relates to benzofuran derivatives of the formula I.

in which

R is 1-piperazinyl, 4-R 1 -piperazinyl or L,

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazinyl-1-ylcarbonyl, N,N-di(tert-butyloxy-carbonyl)aminocarbonyl, —CH═C(R 5 R 6 ), benzofuran-2-yl-C≡C—, —C(Hal) 3 , —CO—C (Hal) 3 , 1,4-dihydrobenzo[d][1,2]oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

L is Cl, Br, I or a free or reactive functionally modified OH group,

R 1 , R 4 in each case independently of one another are H, benzyl or another amino protective group,

R 2 , R 3 in each independently of one another are H or alkyl having 1-6 C atoms,

R 5 , R 6 in each case independently of one another are alkyl having 1-6 C atoms,

Hal is F, Cl, Br or I,

and their salts.

Similar compounds are disclosed in DE 43 33 254 and DE 195 14 567.

The invention was based on the object of finding novel compounds which can be used, in particular, as intermediates in the synthesis of medicaments, but can also be used directly for the production of medicaments.

It has been found that the compounds of the formula I and their salts are important intermediates for the production of medicaments and at the same time have pharmacological properties. Thus, they show, for example, effects on the central nervous system.

The invention relates to the benzofuran derivatives of the formula I and their salts.

Above and below, the radicals R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R, R′, L, Q and Q′ have the meanings indicated in the formulae I to V, if not expressly stated otherwise. In the above formulae, A has 1 to 4, preferably 1, 2 or 3, C atoms. A is preferably methyl or ethyl, furthermore propyl or isopropyl, and additionally also butyl, isobutyl, sec-butyl or tert-butyl. The radical Ph is phenyl.

In the compounds of the formula [sic] I, II, V, VI and VII, L, Q and Q′ are preferably Cl, Br, I or a reactive modified OH group such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arysulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

The expression “amino protective group” is generally known and relates to groups which are suitable for protecting (for blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule. Typical of such groups are, in particular, unsubstituted acyl, aryl, aralkoxymethyl or aralkyl groups. As the amino protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise uncritical; preferred groups, however, are those having 1-20, in particular 1-8 C atoms. The expression “acyl group” is to be interpreted in the widest sense in connection with the present process and the present compounds. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and also, in particular, alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of acyl groups of this type are alkanoyl such as acetyl, propionyl, butyryl; aralkanoyl such as phenylacetyl; aroyl such as benzoyl or toluyl; aryloxyalkanoyl such as phenoxyacetyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butoxycarbonyl), 2-iodoethoxycarbonyl; aralkyloxycarbonyl such as CBZ (carbobenzoxycarbonyl, also called “Z”), 4-methoxybenzyloxycarbonyl, FMOC (9-fluorenylmethoxycarbonyl); arylsulfonyl such as Mtr (4-methoxy-2,3,6-trimethylphenylsulfonyl). Preferred amino protective groups are BOC and Mtr, and additionally CBZ or FMOC.

The compounds of the formula I can have one or more chiral centres and therefore occur in various stereoisomeric forms. The formula I includes all these forms.

The invention further relates to a process for the preparation of benzofuran derivatives of the formula I according to claim 1 and of their salts, characterized in that

a) for the preparation of compounds of the formula I in which

R is Cl, Br, I, 1-piperazinyl or 4-R 1 -piperazinyl and

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazin-1-yl carbonyl, 1,4-dihydrobenzo[d] [1,2]-oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

a compound of the formula II

in which

R is Cl, Br, I, 1-piperazinyl or 4-R 1 -piperazinyl and

Q is Cl, Br, I or a free or reactive functionally modified OH group,

and R 1 has the meaning indicated in claim 1

is reacted with a compound of the formula III

›R′—H  III · 1 of 2

in which

R′ is 2-R 2 -5-R 3 -pyrrol-1-yl, 4-R 4 -piperazin-1-yl, 1,4-dihydrobenzo[d][1,2]oxazin-3-yl or 3,4-dihydrobenzo-1H-phthalazin-2-yl,

and R 2 , R 3 and R 4 have the meanings indicated in claim 1, or

b) for the preparation of compounds of the formula I in which

R is Cl, Br, I, 1-piperazinyl or 4-R 1 -piperazinyl and

R′ is —CH═C(R 5 R 6 ), benzofuran-2-yl-C≡C—, —C(Hal) 3 or —CO—C(Hal) 3 ,

and R 1 , R 5 and R 6 have the meanings indicated in claim 1,

i) a compound of the formula IV

in which

R is Cl, Br, I, 1-piperazinyl or 4-R 1 -piperazinyl, is reacted with a compound of the formula V

Q′—CH 2 —CO—R′  V

in which R′ is —CH═C(R 5 R 6 ), benzofuran-2-yl-C-≡C—, —C(Hal) 3 or —CO—C(Hal) 3 ,

and Q′ is Cl, Br, I or a free or reactive functionally modified OH group,

and R 5 and R 6 have the meanings indicated in claim 1, or

ii) a compound of the formula Va

in which R and R′ have the meanings indicated under i) is cyclized, or

c) a compound of the formula I,

in which R is a 1-piperazinyl radical, is converted by introduction of an amino protective group into another compound of the formula I in which R is the 4-R 1 -piperazinyl radical,

in which R 1 is an amino protective group, or

d) a compound of the formula I,

in which R is a 4-R 1 -piperazinyl group, in which R 1 is benzyl or another amino protective group, is converted by removal of the benzyl or amino protective group into a compound of the formula I in which R 1 is 1-piperazinyl, or

e) in a compound of the formula I a radical R is converted into another radical R

by, for example,

i) replacing a Br atom by OH,

ii) esterifying an OH group or

iii) replacing a Br atom by a 4-R 1 -piperazinyl group, in which R 1 is benzyl or an amino protective group,

and/or a base of the formula I is converted into one of its salts by treatment with an acid.

The compounds of the formula I′ and also the starting substances for their preparation are otherwise prepared by methods known per se, such as are described in the literature (e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), namely under reaction conditions which are known and suitable for the reactions mentioned. In this case, use can also be made of variants which are known per se but not mentioned here in greater detail.

If desired, the starting substances can also be formed in situ such that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the formula I.

In the compounds of the formula II, the radical Q is preferably Cl or Br; however, it can also be I, OH or a reactive modified OH group such as alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy, 1- or 2-naphthalenesulfonyloxy). In the compounds of the formula II, the radical R is preferably Br or 4-benzylpiperazinyl. The compounds of the formula II are known in some cases; the unknown compounds can easily be prepared analogously to the known compounds.

The reaction of the compounds of the formula II with compounds of the formula III proceeds according to methods such as are known from the literature for the alkylation of amines. The components can be fused with one another without a solvent being present, if appropriate in a closed tube or in an autoclave. However, it is also possible to react the compounds in the presence of an inert solvent. Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitrites such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); carbon disulfide; nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate, and optionally also mixtures of the solvents mentioned with one another or mixtures with water.

The addition of an acid-binding agent, for example of an alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or of another salt of a weak acid of the alkali metals or alkaline earth metals, preferably of potassium, sodium or calcium, or the addition of an organic base such as triethylamine, dimethylamine, pyridine or quinoline or of an excess of the amine component can be favourable. Depending on the conditions used, the reaction time can be between a few minutes and 14 days, and the reaction temperature between 0 and 150°, normally between 20 and 130° C.

In the compounds of the formula V, the radical Q′ is preferably Cl or Br; however, it can also be I, OH or a reactive modified OH group such as alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy, or 1- or 2-naphthalenesulphonyloxy).

In the compounds of the formula IV, the radical R is preferably Br or 4-benzylpiperazinyl.

The reaction of the compounds of the formula IV with compounds of the formula V proceeds according to methods such as are known from the literature for the alkylation of phenols.

The compounds of the formula VI are known in some cases; the unknown compounds can easily be prepared analogously to the known compounds. The cyclization is carried out according to generally known methods.

The removal of an amino protective group from a compound of the formula I—depending on the protective group used—is carried out, for example, using strong acids, expediently using TFA (trifluoracetic acid) or perchloric acid, but also using other strong inorganic acids such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids such as trichloroacetic acid or sulfonic acids such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but not always necessary.

›R′—H  III · 2 of 2

Suitable inert solvents are preferably organic solvents, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as dimethylformamide, halogenated hydrocarbons such as dichloromethane, in addition also alcohols such as methanol, ethanol or isopropanol, and water. In addition, mixtures of the abovementioned solvents are possible. TFA is preferably used in an excess without addition of a further solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid, in the ratio 9:1. The reaction, temperatures are expediently between approximately 0 and approximately 50°; the reaction is preferably carried out between 15 and 30°.

The group BOC is preferably removed using TFA in dichloromethane or using approximately 3 to 5 N hydrochloric acid in dioxane at 15-30°.

Hydrogenolytically removable protective groups (e.g. CBZ or benzyl) can be removed, for example, by treating with hydrogen in the presence of a catalyst (e.g. of a noble metal catalyst such as palladium, expediently on a support such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols such as methanol or ethanol or amides such as DMF. The hydrogenolysis is generally carried out at temperatures between approximately 0 and 100° and pressures between approximately 1 and 200 bar, preferably at 20-30° and 1-10 bar.

Compounds of the formula I in which R′ is N,N-di(tert-butyloxycarbonyl)aminocarbonyl are preferably obtained by reaction of the unprotected aminocarbonyl compound, in which

R is 4-R 1 -piperazinyl or L,

L [lacuna] the meaning indicated in claim 1 and

R 1 is benzyl or another amino protective group, with (BOC) 2 O in an inert solvent, such as, for example, THF or dioxane with addition of a base, such as, for example, diethylamine and preferably of a catalytic amount of dimethylaminopyridine.

A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. Suitable acids for this reaction are in particular those which give physiologically acceptable salts. Thus, inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as ortho-phosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxy-ethanesulfonic acid, benzenesulfonic acid, p-toluene-sulfonic acid, naphthalenemono- and -disulfonic acids, and laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and/or purification of the compounds of the formula I.

On the other hand, compounds of the formula I can be converted using bases (e.g. sodium or potassium hydroxide or carbonate) into the corresponding metal, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.

The invention furthermore relates to the use of the compounds of the formula I as intermediates for the synthesis of medicaments. Corresponding medicaments-are described, for example, in DE 4333254.

The invention relates in particular to the use of the compounds of the formula I as intermediates for the synthesis of medicaments which exhibit actions on the central nervous system. 1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its salts are very particularly preferably to be mentioned here.

The invention accordingly relates in particular to the use of the compounds of the formula I according to claim 1

in which

R is Cl, Br, I or 4-R 1 -piperazinyl,

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazin-1-yl carbonyl, 1,4-dihydrobenzo[d][1,2]oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

R 1 is benzyl or another amino protective group,

R 4 is H, benzyl or another amino protective group,

R 2 , R 3 in each case independently of one another are H or alkyl having 1-6 C atoms,

in the synthesis of

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its salts, characterized in that

3-R-6-hydroxybenzaldehyde,

in which R is Cl, Br or I,

is reacted with a compound of the formula VI

X—CH 2 —CO—Q  VI

in which X is Cl, Br, I or a free or functionally modified OH group,

Q is OH or OR″ and

R″ is alkyl having 1-6 C atoms,

to give a compound of the formula VII

in which

R is Cl, Br or I,

and Q has the meanings indicated,

in that, in the compound thus obtained, Q is converted into Cl, Br, I or a functionally modified OH group,

in that the compound thus obtained is reacted with a compound of the formula III

›R′—H  III

in which

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazin-1-ylcarbonyl, 1,4-dihydrobenzo[d][1,2]oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

and R 2 , R 3 and R 4 have the meanings indicated,

to give a compound of the formula I

in which

R is Cl, Br or I,

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazin-1-ylcarbonyl, 1,4-dihydrobenzo[d][1,2]oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

R 4 is H, benzyl or another amino protective group,

R 2 , R 3 in each case independently of one another are H or alkyl having 1-6 C atoms,

in that, in the compound of the formula I thus obtained, the radical R is converted into another radical R,

by reacting under transition metal catalysis with a compound of the formula VIII

4-R 1 -piperazine  VIII

in which

R 1 is benzyl or another amino protective group,

to give a compound of the formula I

in which

R is 4-R 1 -piperazinyl,

R′ is 2-R 2 -5-R 3 -pyrrol-1-ylcarbonyl, 4-R 4 -piperazin-1-ylcarbonyl, 1,4-dihydrobenzo[d][1,2]oxazin-3-ylcarbonyl or 3,4-dihydrobenzo-1H-phthalazin-2-ylcarbonyl,

R 1 is benzyl or another amino protective group,

R 4 is H, benzyl or another amino protective group,

R 2 , R 3 in each case independently of one another are H or alkyl having 1-6 C atoms,

in that the compound thus obtained of the formula I

i) is first converted by basic hydrolysis into a compound of the formula IX and/or its acid addition salt

in which

R is 4-R 1 -piperazinyl and

R 1 is benzyl or another amino protective group,

and then converted using ammonia into a compound of the formula X

in which

R is 4-R 1 -piperazinyl and

R 1 is benzyl or another amino protective group, or

ii) converted directly using ammonia into a compound of the formula X

in which

R is 4-R 1 -piperazinyl and

R 1 is benzyl or another amino protective group,

in that the compound of the formula X thus obtained is converted into 5-(1-piperazinyl)benzofuran-2-carboxamide or an acid addition salt by removal of the amino protective group R 1 , and

in that 5-(1-piperazinyl)benzofuran-2-carboxamide is reacted with 3-(4-chlorobutyl)-5-cyanoindole to give 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and

optionally converted into its acid addition salt.

3-(4-Chlorobutyl)-5-cyanoindole is disclosed in DE 4101686; 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine is disclosed in DE 4333254.

Above and below, all temperatures are indicated in ° C. In the following examples “customary working up” means: water is added, if necessary, the solution is adjusted, if necessary, to a pH between 2 and 10 depending on the constitution of the final product, and extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate, evaporated and purified by chromatography on silica gel and/or by crystallization. R f values on silica gel.

›Examples7
›EXAMPLE 1

(2,5-Dimethylpyrrol-1-yl)-5-bromobenzofuran-2-yl-methanone

0.3 g of sodium hydride (60% suspension in paraffin oil) is introduced into 10 ml of THF and 0.5 mL [sic] of 2,5-dimethylpyrrole in 10 ml of THF is added dropwise (5 minutes). After stirring at 50° C. for 1 hour, a reddish suspension is present. 1.3 g of 5-bromobenzofuran-2-carbonyl chloride in 10 ml of THF is [sic] added dropwise at 25° C. (5 minutes) and the mixture is subsequently stirred for 2 hours. The addition of 100 ml of completely deionized water and 100 ml of ethyl acetate follows. The separated organic phase was additionally washed 2× with 100 ml of water and concentrated in vacuo. After chromatography on silica gel (eluent heptane/ethyl acetate 4:1), the residual oil gives 700 mg of yellow crystals (yield 44%), m.p. 115-116°.

›EXAMPLE 2

5-Bromobenzofuran-2-carboxylic Acid Diethylamide

1.3 g. of 5-bromobenzofuran-2-carbonyl chloride, 1 mL [sic] of ethyldiisopropylamine and 30 mL [sic] of toluene are mixed and 0.62 ml of diethylamine is added to the brown-coloured solution with stirring. A precipitate is formed with a slightly exothermic reaction. After 5 minutes, the mixture was treated with 30 ml of completely deionized water and the phases were separated. The organic phase was washed with 1.) 20 ml of iN HCl 2.) 20 ml of iN NaOH 3.) 20 ml of water and then with 20 ml of saturated NaCl solution and then freed of solvent components in vacuo. After chromatography on silica gel the residual, yellowish oil forms in the eluent MtB ether/heptane 2:1 [sic]. Final weight: 1.3 g of colourless crystals [sic] (yield: 88%), m.p. 79-81°.

›EXAMPLE 3

Di-tert-Butyl N-(5-Bromobenzofuran-2-carbonyl)imidodicarbonate

12 g of 5-bromobenzofuran-2-carboxamide, 23.5 ml of BOC 2 O, 600 mg of DMAP and 8 ml of triethylamine are introduced into 100 ml of THF at 20° C. A clear, orange solution is formed in 3 h in an endothermic reaction. It is warmed to 25° C. and treated with 100 ml of water and 100 ml of ethyl acetate. The organic phase is separated off, and washed twice with 100 ml of water and 100 ml of saturated sodium chloride solution. The organic phase is concentrated and forms a mixture of oil and crystals (22 g/yield 40%). After crystallization of the crude product from 160 ml of ethanol, 9.0 g of yellow crystals are obtained, m.p. 138-139°.

›EXAMPLE 4

5-Bromobenzofuran-2-carboxylic Acid Dibenzylamide

A solution of 50 ml of toluene and 7.9 g of dibenzylamine are added dropwise with stirring at 50-60° C. in the course of 10 min. to 5.2 g of 5-bromobenzofuran-2-carbonyl chloride in 100 ml of toluene. A colourless solid is obtained. After dropwise addition is complete, the mixture is additionally stirred at 100-110° C. for a further 3 hours. After cooling to 10° C., the solid product (dibenzylammonium chloride) is filtered off with suction. The filtrate is then treated with a mixture of 150 ml of water and 10 g of sodium carbonate and thoroughly shaken. The organic phase is separated off, washed again with 100 ml of water, dried using sodium sulfate and filtered. The, filtrate is concentrated on a Rotavapor in vacuo to a residue (residue: 9.5 g). After recrystallization from 100 ml of methanol, 6.5 g of product (yield 77%) remain after isolation.

m.p. 114-115°.

›EXAMPLE 5

5-(4-Benzylpiperazin-1-yl)bromobenzofuran-2-carboxylic Acid Dibenzylamide

0.06 mg of Pd2DBA3 [sic] and 0.007 g of 2-dicyclohexylphosphino-2′-dimethylaminobiphenyl in 40 ml of toluene was stirred under nitrogen at 25° C. for 20 min. 1.58 g of 5-bromo-2,3-dihydrobenzofuran-2-carboxylic acid dibenzylamide, 0.98 g of 1-benzylpiperazine and 1.43 g of sodium tert-butylate are then added and the mixture is stirred at 120° C. for 2 hours. The cooled reaction mixture is stirred into a mixture of 150 ml of water and 5 ml of 37% hydrochloric acid with stirring [sic]. The reaction mixture is neutralized with 1.5 g of sodium carbonate and the phase is [sic] extracted 3 times with 100 ml of ethyl acetate. The combined organic phases are dried with 5 g of sodium sulfate and the filtrate is concentrated in vacuo to give a resinous residue (1.8 g of crude product). The crude product is dissolved in 100 ml of ethyl acetate, clarified with activated carbon and filtered. By addition of 25 ml of 2-molar ethanolic hydrochloric acid, the piperazine product is precipitated as the hydrochloride, filtered, and the crystals are washed with 10 ml of ethyl acetate and dried in vacuo at 40° C. Final weight: 1.5 g/yield 53%, m.p. 196-198°.

›EXAMPLE 6

cis/trans-1,2-Di(5-Bromobenzofuran)-2-ylethene

A) Preparation of the Diether

The compound is obtained by reaction of 5-bromosalicylaldehyde with Cl—CH 2 —CH═CH—CH 2 —Cl.

B) The Dibenzofuran Derivative is Obtained by Cyclization.

›EXAMPLE 7

2,2′-Ethyndiyl-bis-5-bromobenzofuran

A) Preparation of the diether

Reaction of 5-bromosalicylaldehyde with Cl—CH 2 —CC—CH 2 —Cl.

B) Cyclization of the Diether.

1 of 11 part labels are ours — the grant heads the rest

Claims

16 · 3 independent · depth 3
12345678910111213141516
16 granted claims

Classifications

22 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K31/4025
  • A61P25/00
  • A61K31/497
  • A61K31/536
  • A61K31/502
  • A61K31/343
  • A61K31/496
  • A61K31/4178
Section C — Chemistry; metallurgy
  • C07D307/85
  • C07D413/06
  • C07D405/06
  • C07D307/80
  • C07B61/00
  • C07D307/79
USPC · US Patent Classification
514/422514/252.13514/469544/359514/254.1549/469544/357548/525

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJul 2000Oct 2000Jan 2001Apr 2001Jul 2001Oct 2001Jan 2002Apr 2002Jul 2002Oct 2002Jan 2003Apr 2003USPTOApplicantNon-final rejectionResponse after non-final
USPTOApplicanthover for detail · click to open
Pendency
2.7 y
985 days filing → grant
Office actions
1
non-final + final
Responses
1
no RCE
Examiner
Amelia Owens
art unit 1625 · TC 1600
Citations: 5 back · 4 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Chain of title

⤢ drag to zoom2002200420062008201020122014201620182020Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Worldwide family

48 members · 29 offices
US1EP2JP2KR2CN2WO2AR1AT1AU2BR3CA2CZ2DE2DK1ES1HK2HU3IL2MX1MY1NO3PL2PT1RU1SI1SK2TR1UA1ZA1
this patentIP5 & PCTother officessolid = grantedhover for detail · click to open
Members
48
DOCDB simple family 7914351
Offices
29
US · EP · JP · KR · CN · WO
Granted
12 of 48
grant date present
Non-English titles
25
shown as filed, never translated
›IP5 & PCT — 11 members
OfficePublicationKindPublishedFiledStatusTitle
USthis patentUS-6531503-B1B111 Mar 200329 Jun 2000grantedBenzofurane derivatives
EPEP-1194426-A2A210 Apr 200229 Jun 2000publishedDerives de benzofuranfr
EPEP-1194426-B1B118 Aug 200429 Jun 2000grantedDerives de benzofuranfr
JPJP-2003504364-AA4 Feb 200329 Jun 2000publishedベンゾフラン誘導体ja
JPJP-4908706-B2B24 Apr 201229 Jun 2000grantedベンゾフラン誘導体ja
KRKR-20020016815-AA6 Mar 200229 Jun 2000published벤조퓨란 유도체ko
KRKR-100709378-B1B120 Apr 200729 Jun 2000granted벤조퓨란 유도체ko
CNCN-1356996-AA3 Jul 200229 Jun 2000published苯并呋喃衍生物zh
CNCN-1178934-CC8 Dec 200429 Jun 2000grantedBenzofuran derivatives
WOWO-0104112-A2A218 Jan 200129 Jun 2000publishedBenzofuranderivatede
WOWO-0104112-A3A32 Aug 200129 Jun 2000publishedBenzofuranderivatede
›Other offices — 37 members
OfficePublicationKindPublishedFiledStatusTitle
ARAR-024671-A1A123 Oct 20027 Jul 2000publishedDerivados del benzofurano, un procedimiento para su preparacion, y el empleo de los mismos como productos intermedios para la sintesis de medicamentoses
ATAT-E273973-T1T115 Sep 200429 Jun 2000grantedBenzofuranderivatede
AUAU-6266500-AA30 Jan 200129 Jun 2000publishedBenzofurane derivatives
AUAU-767413-B2B26 Nov 200329 Jun 2000grantedBenzofurane derivatives
BRBR-0012329-AA19 Mar 200229 Jun 2000publishedDerivados de benzofuranopt
BRBR-0012329-B1B119 Mar 201329 Jun 2000publishedderivados de benzofurano, processo para sua preparaÇço e uso dos mesmos.pt
BRBR-PI0012329-B8B825 May 202129 Jun 2000publishedderivados de benzofurano, processo para sua preparação e uso dos mesmos.pt
CACA-2378603-A1A118 Jan 200129 Jun 2000publishedDerives de benzofuranfr
CACA-2378603-CC11 May 201029 Jun 2000grantedBenzofuran derivatives
CZCZ-200211-A3A317 Apr 200229 Jun 2000publishedDerivát benzofuranu, způsob jeho přípravy a jeho pouľitícs
CZCZ-301441-B6B63 Mar 201029 Jun 2000publishedMethod and intermediate for preparing 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine
DEDE-19932314-A1A111 Jan 200110 Jul 1999publishedBenzofuranderivatede
DEDE-50007501-D1D123 Sep 200429 Jun 2000grantedBenzofuranderivatede
DKDK-1194426-T3T320 Dec 200429 Jun 2000grantedBenzofuranderivaterda
ESES-2226884-T3T31 Apr 200529 Jun 2000grantedDerivados de benzofurano.es
HKHK-1047275-A1A114 Feb 200329 Jun 2000publishedBenzofurane derivatives
HKHK-1047275-BB2 Sep 200529 Jun 2000publishedBenzofurane derivatives
HUHU-P0201903-A2A228 Oct 200229 Jun 2000publishedBenzofurane derivatives and process for producing them
HUHU-P0201903-A3A328 Feb 200529 Jun 2000publishedBenzofurane derivatives and process for producing them
HUHU-229135-B1B128 Aug 201329 Jun 2000publishedBenzofurane derivatives
ILIL-147494-A0A014 Aug 200229 Jun 2000publishedBenzofuran derivatives
ILIL-147494-AA20 Mar 20086 Jan 2002publishedBenzofuran derivatives
MXMX-PA02000316-AA30 Jul 200229 Jun 2000publishedBenzofurane derivatives.
MYMY-122667-AA29 Apr 20066 Jul 2000publishedBenzofuran derivatives
NONO-20020095-D0D09 Jan 20029 Jan 2002publishedBenzofuranderivaterno
NONO-20020095-LL9 Jan 20029 Jan 2002publishedBenzofuranderivaterno
NONO-328209-B1B111 Jan 20109 Jan 2002publishedBenzofuranderivater, anvendelser derav ved fremstilling av 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)piperazin og for fremstilling av medikamenterno
PLPL-353157-A1A120 Oct 200329 Jun 2000publishedBenzofurane derivatives
PLPL-196477-B1B131 Jan 200829 Jun 2000publishedBenzofurane derivatives
PTPT-1194426-EE31 Jan 200529 Jun 2000publishedDerivados de benzofuranopt
RURU-2278862-C2C227 Jun 200629 Jun 2000grantedBenzofuran derivatives
SISI-1194426-T1T128 Feb 200529 Jun 2000publishedBenzofurane derivatives
SKSK-62002-A3A39 May 200229 Jun 2000publishedBenzofurane derivative, process for the preparation thereof and pharmaceutical composition comprising same
SKSK-287360-B6B69 Aug 201029 Jun 2000publishedBenzofurane derivative, its use for the preparation of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5- yl)piperazine and as intermediate product in the synthesis of medicaments
TRTR-200200017-T2T221 May 200229 Jun 2000publishedBenzofuran türevleritr
UAUA-73310-C2C215 Jul 200529 Jun 2000publishedBenzofuran derivatives and a method for the preparation thereof
ZAZA-200201085-BB30 Jul 20037 Feb 2002publishedBenzofurane derivatives.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock